$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
Market Whales and Their Recent Bets on BNTX Options
Novavax COVID-19 Vaccines Now Available
US stock preview | Earnings guidance exceeds expectations! Oracle continues to rise more than 6% pre-market; Is the US stock correction over? Deutsche Bank: Three major bullish factors may support new highs in US stocks.
The Q4 revenue outlook does not highlight the profitability improvement of AI, and Adobe's pre-market plunge exceeds 8%; Fitch: The Fed's rate cut should be gradual rather than hasty, and is expected to make a moderate 250 basis point rate cut over the next two years; Will the Fed's rate cut signal be sounded? Goldman Sachs executives highly recommend small-cap stock hunting.
Marengo Therapeutics Enters Clinical Study Collaboration And Supply Agreement With Gilead Sciences
US stocks closed: Technology breaks through to lift the index, Nasdaq and S&P jointly achieve four consecutive gains.
① After four consecutive days of gains, the S&P 500 index is still 1.3% away from its historical high. ② Warren Buffett's deputy sold more than half of Berkshire Hathaway's positions, causing the stock price to fall for the seventh consecutive day. ③ AirPods Pro transforms into an OTC hearing aid, with FDA approval for Apple's hearing assistance software. ④ Gilead's HIV prevention drug delivers positive results once again.
Gilead Sciences Goes Ex-dividend Tomorrow
Cracking The Code: Understanding Analyst Reviews For Exact Sciences
Gilead's "HIV prevention" drug has achieved amazing results again! The effectiveness rate is as high as 96%.
① The results showed that among the 2,180 participants in the lenacapavir group, there were only 2 new cases, and 99.9% of the participants did not become infected with HIV, resulting in a relative risk reduction of 96%. ② The press release also mentioned the results of the "PURPOSE 1" trial released in June - there were zero cases of HIV infection among the 2,134 women in the lenacapavir group.
What the Options Market Tells Us About Gilead Sciences
New Additions to Roth MKM's ADR Portfolio for September
Gilead Posts Second Late-stage Win for Twice-yearly HIV Therapy
US stocks outlook: August PPI slightly lower than expected, three major futures indexes slightly lower; downgraded by major banks! Micron Technology pre-market fell more than 3%
Goldman Sachs CEO: There are signs of weakness in the job market, and the Fed may still cut interest rates by 50 basis points. UBS Group CEO: The market's expectation for a rate cut by the Fed is too aggressive, bullish on a soft landing for the US economy. Nvidia soared 8% overnight and saved the US stock market! Multiple call options made 10 times the profit.
Gilead Shares Are Trading Higher After the Company Announced Interim Results From a Phase 3 Trial Showing That Twice-yearly Lenacapavir Reduced HIV Infections by 96%.
Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Exact Sciences Analyst Ratings
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Beigene's stock price was hit by bearish news! It is accused of stealing trade secrets. The company denies the accusations and vows to vigorously defend itself.
①AbbVie has once again filed a lawsuit against Beigene, accusing Beigene of stealing core business secrets to develop BTK degraders. ②Previously, AbbVie sued Beigene for patent infringement of zanubrutinib (BTK inhibitor), and the case is under review. Beigene stated that this has not had a negative impact on the research and sales of zanubrutinib in the United States.
Exact Sciences Spikes Ahead of Data for Blood-based Cancer Test